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Background: Over time, a patient-centered evaluation of health status has become more 
important for systemic sclerosis (SSc), both in research and clinical setting. Patient-reported 
outcomes (PROs) are being increasingly used to measure various domains of disease status 
relevant to patients and physicians. The EULAR Outcome Measures Library (OML) is a freely 
available website with structured access to a growing database of validated PROs [1], but 
currently there are no PROs available on SSc at the EULAR OML. 
Objectives: To provide a comprehensive review of validated SSc-specific PROs and to critically 
appraise their validity. 
Methods: A sensitive search was developed in Medline and Embase (08/2015) to identify all 
validation studies, cohort studies, reviews or metaanalyses in which the objective were the 
development or validation of PROs evaluating organ involvement, disease activity or damage in 
SSc. A reviewer screened title and abstracts, selected the studies, and collected data concerning 
validation using ad hoc forms based on the COSMIN checklist. 
Results: From 13,140 articles captured, 74 met the predefined criteria. After excluding an 
instrument for the unavailability of an English version, the selected studies provided information 
on 6 SSc-specific PROs: the Scleroderma Assessment Questionnaire (SAQ), the scleroderma 
functional score (FS), the Raynaud's condition score (RCS), the Mouth Handicap in SSc 
(MHISS), the University of California Los Angeles-Scleroderma Clinical Trial Consortium Gastro-
Intestinal tract (UCLA-SCTC-GIT 2.0), and the Skin Self-Assessment. The table summarizes the 

























































































MID 14–15 points 
(0–100 VAS)PASS 
34 points 
































































Conclusions: Six SSc-specific PROs have a minimum validation and will be included in the 
EULAR OML. In general, the level of validation attained could be improved. Further development 
in the area of disease-specific PROs in SSc is warranted. 
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